Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0730

Related search